With $80M, ReCode Looks to Advance RNA Therapies for Lung Diseases

Two companies working on treatments for rare genetic lung diseases have combined efforts and raised $80 million to bring into human testing next year two investigational treatments that use types of RNA to tweak mutated proteins. Dallas company ReCode Therapeutics and Menlo Park, CA-based TranscripTx have merged under the ReCode name and leadership of CEO […]

Click to view original post